Takeover of BioXell: Prospectus of Cosmo has been published

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Milan, Italy, 8 December 2009 - As announced on November 18, 2009,
Cosmo Pharmaceuticals S.p.A. (SIX Swiss Exchange: COPN),
headquartered in Lainate, Italy, has published the offer prospectus
today in which a public tender offer is made to the shareholders of
BioXell S.p.A. (SIX Swiss Exchange: BXLN).

The detailed terms of the Offer are set out in Cosmo's offer
prospectus of today. The offer prospectus of Cosmo (including the
report of the board of directors of BioXell) can be downloaded at
www.cosmopharmaceuticals.com.

About BioXell
BioXell is a listed biopharmaceutical company focused on the
discovery and development of drugs that exploit novel mechanisms of
action. Following the conclusion of its Vitamin D3 related R&D
activities BioXell has been looking into a number of strategic
options in line with the demands of its shareholders.

BioXell was founded in 2002 as a spin-out from Roche. In June 2006,
BioXell listed its shares on the main segment of the SIX Swiss
Exchange. The company is located in Milan, Italy.

More information on BioXell can be found at: www.bioxell.com

About Cosmo
Cosmo is a specialty pharmaceutical company that aims to become a
global leader in optimised therapies for certain Gastrointestinal
Diseases. The company's proprietary clinical development pipeline
specifically addresses innovative treatments for IBD, such as
Ulcerative Colitis and Crohn's Disease, and Colon Infections. Cosmo's
first MMX(TM) product that has reached the market is Lialda(TM) /
Mezavant®, a treatment for IBD that is licensed globally to Giuliani
and Shire Limited. Cosmo's proprietary MMX® technology is at the core
of the company's product pipeline and was developed from its
expertise in formulating and manufacturing gastrointestinal drugs for
international clients at its GMP (Good Manufacturing Practice)
facilities in Lainate, Italy. The technology is designed to deliver
active ingredients in a targeted manner in the intestines.

More information on Cosmo can be found at:
www.cosmopharmaceuticals.com

For further information, please contact:

BioXell Dynamics Group SA
Alvise Sagramoso, Chief Administrative Christophe Lamps
Officer
Tel: +39 (0)2 210 49 550 Tel: +41 (0)22 308 62 22
Fax: +39 (0)2 700 59 926 Fax: +41 (0)22 308 62 36
alvise.sagramoso@bioxell.com cla@dynamicsgroup.ch

This press release can be downloaded at www.bioxell.com.

Disclaimer
This document does not constitute, or form part of, any offer to
purchase or sell any shares or other securities and neither it nor
any part of it shall form the basis of, or be relied upon in
connection with any contract or commitment whatsoever. Any decision
to tender shares must be based on the official offer documents. This
document does also not constitute a pre-announcement or an offering
prospectus pursuant to Swiss laws or any other laws.

This press release does not constitute or form part, or all, of any
offer or invitation to sell or issue, or any solicitation of any
offer to purchase or subscribe for, any securities, nor shall part,
or all, of these materials or their distribution form the basis of,
or be relied on in connection with, any contract or investment
decision in relation to any securities. This press release contains
forward-looking statements based on the currently held beliefs and
assumptions of the management of BioXell, which are expressed in good
faith and, in their opinion, reasonable. Forward-looking statements
involve known and unknown risks, uncertainties and other factors,
which may cause the actual results, financial condition, performance,
or achievements of BioXell, or industry results, to differ materially
from the results, financial condition, performance or achievements
expressed or implied by such forward-looking statements. Given these
risks, uncertainties and other factors, recipients of this document
are cautioned not to place undue reliance on these forward-looking
statements. BioXell disclaims any obligation to update these
forward-looking statements to reflect future events or developments.

--- End of Message ---

bioXell S.p.A
via Olgettina 58 Milan Italy

WKN: A0J3MW; ISIN:
IT0004069933 ;
Listed: Main Market in SIX Swiss Exchange;
Copyright © Hugin AS 2009. All rights reserved.